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A B S T R A C T
This toxicogenomic study was conducted to predict (post)menopausal human health eﬀects of commercial soy
supplementation using ovariectomized rats as a model. Diﬀerent target tissues (i.e. breast, uterus and sternum)
and non-target tissues (i.e. peripheral blood mononuclear cells (PBMC), adipose and liver) of ovariectomized
F344 rats exposed to a commercially available soy supplement for eight weeks, were investigated. Changes in
gene expression in these tissues were analysed using whole-genome microarray analysis. No correlation in
changes in gene expression were observed among diﬀerent tissues, indicating tissue speciﬁc eﬀects of soy iso-
ﬂavone supplementation. Out of 87 well-established estrogen responsive genes (ERGs), only 19 were found to be
signiﬁcantly regulated (p < 0.05) in diﬀerent tissues, particularly in liver, adipose and uterus tissues.
Surprisingly, no ERGs were signiﬁcantly regulated in estrogen sensitive breast and sternum tissues. The changes
in gene expression in PBMC and adipose tissue in rats were compared with those in (post)menopausal female
volunteers who received the same supplement in a similar oral dose and exposure duration in human inter-
vention studies. No correlation in changes in gene expression between rats and humans was observed. Although
receiving a similar dose, in humans the plasma levels expressed as total free aglycones were several folds higher
than in the rat. Therefore, the overall results in young ovariectomized female F344 rats indicated that using rat
transcriptomic data does not provide a suitable model for human risk or beneﬁt analysis of soy isoﬂavone
supplementation.
1. Introduction
The advances in health care and the public initiative towards
healthy living have increased the number of women in the (post)me-
nopausal age group worldwide. The menopause transition results in
declining ovarian functions and leads to signiﬁcant hormonal changes
in the female body, in particular in the reduced production of the fe-
male hormone estrogen. As a result women in this age group face
several physical and mental diﬃculties including hot ﬂashes, night
sweats, vaginal atrophy, and an increased risk of developing osteo-
porosis. Menopause is inevitable and many women during their me-
nopausal period take hormone replacement therapy (HRT) or use soy
based dietary supplements. These soy based supplements contain phe-
nolic plant compounds called isoﬂavones [1,2] which have structural
similarities with estradiol [3]. Despite inconsistencies among the
available data, there is growing evidence supporting the notion that soy
isoﬂavones are eﬀective in the reduction of menopausal symptoms
[4,5]. Therefore, the popularity and availability of soy supplements are
increasing, although concern exists within governmental and public
health related organizations [6,7] regarding the safety of long-term
exposure to self-administrated high levels of soy isoﬂavones, which may
exceed the levels that can be obtained from the diet.
The eﬀects of soy isoﬂavones are thought to be induced via estrogen
receptors (ERs) of which an alpha (ERα) and beta (ERβ) form exist. soy
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isoﬂavones may regulate transcription of ER target genes via the es-
trogen-responsive elements (EREs) present within gene promoter re-
gions in target tissues. It has been shown that ERα activation stimulates
cell proliferation, whereas ERβ activation leads to inhibition of pro-
liferation and stimulation of apoptosis [8–10]. It is known that the re-
lative occurrence of ERα and ERβ is tissue dependent. For example,
ERα is predominant in the mammary gland, the epididymis, testis,
uterus, kidney and the pituitary gland, whereas ERβ is more present in
the prostate, bladder and lungs [11–14]. When (post)menopausal
women produce small amounts of endogenous estradiol, it is possible
that binding of SIF from food supplements to ERs may produce es-
trogen-responsive eﬀects especially in ERβ-sensitive target tissues, be-
cause soy isoﬂavone have been shown to be particularly ERβ-active
[10,11]
During the past decades, the application of microarray technology
has opened up new opportunities to study the eﬀects of food and food
supplements in the control of cellular processes and related health ef-
fects upon exposure to diﬀerent type of compounds [15–17]. By using
transcriptomic techniques it is possible to directly compare changes in
gene expression, not only in diﬀerent tissues of the same species, but
also in similar tissues among diﬀerent species. We investigated whether
a transcriptomic approach using ovariectomized rats would be an
adequate model to predict (post)menopausal health risks and/or ben-
eﬁts of soy isoﬂavone supplementation. Therefore, in the rat study re-
ported here we have investigated the changes in gene expression in
diﬀerent target (i.e. breast, uterus and sternum tissues) and non-target
(PBMC, adipose and liver tissues) tissues of ovariectomized female F344
rats exposed to a commercially available soy supplement for eight
weeks in an oral dose which, on a kg bw base, is similar as the re-
commended dose for humans. In addition, the changes in gene ex-
pression in PBMC in the current study were compared with those of a
previously reported short-term rat study [18]. Finally a cross-species
comparison of changes in gene expression in PBMC and adipose tissues
among ovariectomized rats and (post)menopausal women was carried
out to compare the eﬀects of soy isoﬂavone supplementation in rats
with those observed in (post)menopausal human volunteers. The
overall aim of the present study was to investigate whether such a
toxicogenomic approach could be used to predict possible health eﬀects
in humans, and would improve the health risk/beneﬁt assessment of
soy isoﬂavones.
2. Materials and methods
2.1. Chemicals
Pure isoﬂavone standards (both glucosides and aglycones) and
equol were purchased from LC laboratories (Woburn, MA, USA).
Dimethyl sulfoxide (DMSO) was obtained from Acros Organics (Geel,
Belgium), and enterodiol, β-glucuronidase H-5 (H. Pomatia contain
60,620 unit/g solid), Optiprep™, and Tricine from Sigma-Aldrich
(Steinheim, Germany). NaCl was obtained from VWR International
(Darmstadt, Germany), and acetonitrile and methanol from Biosolve BV
(Valkenswaard, the Netherlands). Oasis HLB 1cc solid phase extraction
cartridges were obtained from Waters (Milford, MA, USA).
2.2. Animals
Twelve female ovariectomized F344 inbred 8 weeks old rats were
purchased from Harlan, (Horst, the Netherlands). The ovariectomy of
these rats was done at the age of 6 weeks by the supplier and after 2
weeks of acclimatization they were delivered at the animal facility, the
Centre for Laboratory Animals (CKP), Wageningen University,
Wageningen, the Netherlands. Six rats were used as control and six
were used for soy isoﬂavone treatment. F344 rats were chosen for
several reasons. Firstly, according to US EPA (Environmental Protection
Agency) [20], the inbred isogenic strain F344 rats are sensitive to
estrogenic compounds and thus particularly suitable to study the eﬀects
of soy isoﬂavones. Secondly, the use of an inbred strain will minimize
the background noise in micro array analysis. Thirdly, for reasons of
comparison, we used the same strain of rats as for the short-term study
and measured PBMC gene expression; this enabled comparison of PBMC
gene expression after long term exposure (present study) and short term
exposure [18].
2.3. Housing and diet
After arrival at the animal facility (i.e. CKP), the rats were housed in
groups (2 animal/cage) and fed an isoﬂavone free RMH-B standard diet
(ABDiets, Woerden, the Netherlands) (Supplementary Table 1) ad li-
bitum. Standard housing, day-light hours and humidity were also
maintained during the whole experimental period. The experiment
started after a week acclimatization period. After that period animals
were about 9 weeks of age with an average body weight of
160.8 ± 9.8 g.
2.4. Animal experiment
All aspects of the experimental protocol were reviewed and ap-
proved by the Animal Welfare Committee of Wageningen University
(Wageningen, the Netherlands) which was in compliance with the
Dutch Act on animal experiment (Stb, 1977, 67; Stb 1996, 565), revised
February 5, 1997. The approval number was 2013015.d. The animals
were dosed a commercial soy containing supplement, corresponding to
a dose of 2mg soy isoﬂavones/kg bw (1 gavage/day) in 1% DMSO
solution for seven days per week, during 8 weeks. One day before sa-
criﬁce the animals received an extra dose in the evening instead of a
dose early next morning. This was done to make the experiment com-
parable with the time schedule of the two human intervention studies
(see below) carried out by the Division of Human Nutrition,
Wageningen University in order to facilitate direct comparison of both
rat and human data after exposure to the same supplement. The dose
level used (i.e. 2 mg soy isoﬂavones/kg body weight per day) provides
the equivalent dose for a female adult consuming the same soy based
supplement. This dose was also selected to provide a direct comparison
with the human intervention studies (mentioned in Section 2.5).
2.5. Related experiments
The eﬀects on gene expression in PBMC and adipose tissue after soy
isoﬂavones intake in the present rat study were compared with the gene
expression data of a previously reported short term rat study, and of
two human intervention studies (see below).
2.5.1. Short term rat study
A short-term (2 days) rat experiment was performed earlier at the
same animal facility centre of Wageningen University, after approval by
the ethical committee on animal experimentation of Wageningen
University. This short-term study, in which rats from the same strain
(i.e. ovariectomized F344) were exposed to a similar soy isoﬂavone
supplement, and also PBMC were collected and studied by microarray
analysis, was mainly designed for quantiﬁcation of the bioavailability
of soy isoﬂavone [18].
2.5.2. Human intervention studies with the same commercial soy
supplement
Two human intervention studies were conducted at the Division of
Human Nutrition of Wageningen University [4,19]. The studies were
approved by the Medical Ethical Committee of this university and re-
gistered at clinicaltrials.gov under number NCT01232751 and
NCT01556737. Both of these studies were double blind cross-over
studies with the exposure time of two eight week intervention periods
and an eight week washout period in between. A total of 30 (post)
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menopausal, equol-producing women with an average age of
61.1 ± 5.8 years were recruited for the ﬁrst human intervention study
in which PBMCs were collected [4]. Twenty six (post)menopausal
women were recruited for the second human intervention study with
the same supplement as the ﬁrst study and in which adipose tissue was
collected [19]. All volunteers were recruited from Wageningen or the
direct surrounding areas. All participants received the same soy sup-
plement as used in the rat studies and 2 capsules in the morning and 2
in the evening after the meal resulting in a dose of about 1.5 mg soy
isoﬂavones/kg bw per day and a placebo treatment.
2.6. Preparation of test solutions
The commercial soy supplement, Phytosoya, was obtained from
Arkopharma (Carros, France). The supplement had a total soy iso-
ﬂavones content of 70.3mg/gram supplement [21]. The content of the
three glucosides; genistin, daidzin and glycitin was 7.54, 40.03 and
22.72mg/g supplement, respectively. An oral gavage dose of 2mg soy
isoﬂavones/kg bw which corresponds with 0.4mg soy isoﬂavones/rat
was applied per day. The stock solutions were freshly prepared daily,
sonicated for 30min and were placed on a multi-axile-rotating-mixture
(CAT RM-40, Laufen, Germany) machine to avoid any aggregation
during the period of gavage dosing. The control rats received a gavage
dose of nanopure water containing 1% DMSO.
2.7. Sample collection and analysis
After the 8 weeks dosing the animals were sacriﬁced after anaes-
thesia with a mixture of isoﬂurane and oxygen followed by removal of
blood from the dorsal aorta with a syringe containing 0.1mL lithium
heparin. The collected blood was immediately transferred into 10mL
tubes and kept on a multi-axle-rotating mixer (CAT RM-40, Laufen,
Germany). The average amount of collected blood was 5–6mL.
Collected blood samples were divided into two parts, one part (3.5 mL)
for isolating PBMC and another part (about 1–2mL) for separating
plasma. The ﬁrst part of the collected blood samples was used for micro
array analysis and the second part was used for measuring the plasma
concentration of soy isoﬂavone. White adipose, breast, uterus, liver,
and sternum tissues were also collected. After collection the tissue
samples were frozen immediately in liquid nitrogen and stored at
−80 °C until further analysis. The plasma samples were prepared by
centrifuging the blood for 5min at 10,000 rpm (Biofuge centrifuge,
Heraeus Sepatech, UK) and were collected in Safe-lock 0.5 mL
Eppendorf tubes (Eppendorf AG, Hamburg, Germany). These samples
were placed on ice during the sample collection of the in vivo experi-
ment and stored at −80 °C until analysis.
2.8. Extraction and analysis of soy isoﬂavones from rat plasma
The enzymatic hydrolysis, solid phase extraction and HPLC (High
Performance Liquid Chromatography) analysis of soy isoﬂavone in
plasma samples were performed as described earlier [19,21]. To avoid
inter laboratory variations among the present in vivo rat study and the
human intervention studies, analysis of soy isoﬂavones concentrations
in plasma and micro-array analysis were performed at the same la-
boratories using similar protocols. Averages and standard deviations of
plasma soy isoﬂavones concentrations of the dose group and the control
were calculated using Microsoft Excel.
2.9. Isolation of rat PBMC, mRNA and running microarray analysis of
diﬀerent tissues
Packages from the Bioconductor project [22], integrated in an on-
line software program [23], were used to analyse the array data. Var-
ious advanced-quality metrics, diagnostic plots, pseudo images, and
classiﬁcation methods were used as described by Heber and Sick [24],
to determine the quality of the arrays before statistical analysis. The
probes on the Rat Gene 1.1 ST array were redeﬁned using current
genome information [25]. In this study, probes were reorganized on the
basis of the gene deﬁnitions available in the National Center for Bio-
technology Information (NCBI) Rattus norvegicus Entrez Gene database,
based on the rat genome build 5.1 (custom CDF v17). Normalized gene
expression estimates were calculated with the Robust Multichip
Average method [26]. Subsequently, the dataset was ﬁltered to only
include probe sets that were active (i.e. expressed) in at least 4 samples,
using the universal expression code (UPC) approach (UPC score>
0.50) [27]. Diﬀerentially expressed probe sets were identiﬁed by using
linear models, applying moderated t-statistics that implemented in-
tensity-based empirical Bayes regularization of standard errors [28,29].
Probe sets with p < 0.05 were considered to be signiﬁcantly regulated.
Changes in gene expression were related to functional changes using
gene set enrichment analysis (GSEA) performed according to Sub-
ramanian et al. [30]. GSEA focuses on groups of genes that share a
common biological, biochemical or metabolic function. GSEA has the
advantage that it is unbiased, because no gene selection step is used.
Only gene sets consisting of more than 15 and less than 500 genes were
taken into account. Gene sets were derived from the Kyoto En-
cyclopedia of Genes and Genomes (KEGG) [31]. Eﬀects of soy iso-
ﬂavones treatment versus control were compared using ranked lists
based on signiﬁcance (t-values), using methods described by Plaisier
et al. [32].
3. Results
Fig. 1 shows an overview of the results from the microarray analysis
of ovariectomized female F344 rats. After normalization and ﬁltering of
a total of 19,311 probe sets, 39–50% probe sets were retained in the
diﬀerent tissues. The percentage of signiﬁcantly regulated (p < 0.05)
genes within this data set amounted to only 1–13.6% (i.e. 74 to 1305
genes out of 7556 to 9561 robust multichip average (RMA) normalized
and UPC ﬁltered genes), and was lowest for the breast tissue (i.e. only
1%), with increasing number of genes being regulated in sternum,
PBMC, liver, adipose and uterus tissues (i.e. 2.3, 6.1, 10.4, 13.6 and
13.6%, respectively). Fig. 1 also shows the number of signiﬁcantly up
and down regulated (false discovery rate, FDR < 0.25) biological
pathways. In line with the total number of signiﬁcantly regulated genes,
the lowest number of signiﬁcantly changed biological pathways was
found in breast tissue (i.e. 68 gene sets) and the highest number in
uterus tissue (i.e. 309 gene sets). In the right column of Fig. 1 the
human homologous genes in PBMC and adipose tissue which were also
found in the rat are indicated. These homologous genes were retrieved
from the human intervention studies mentioned above [4,19]. Out of
6413 and 7731 human homologous genes, only 10 and 88 genes were
signiﬁcantly (p < 0.05) regulated in rat PBMC and adipose tissue, re-
spectively.
As the eﬀects of soy isoﬂvones are considered to be mostly mediated
via the estrogen receptors (ERs), we investigated the number of dif-
ferentially regulated ERGs in the six selected rat tissues. These genes
were selected based on their occurrence in the Dragon DRGs database
(http://datam.i2r.a-star.edu.sg/ergdbV2/). Table 1 shows the list of
ERGs and the direction of their regulation in the diﬀerent rat tissues. It
is shown that out of 87 ERGs available in the speciﬁed website only 19
were found to be signiﬁcantly regulated in the diﬀerent tissues. The
highest number of ERGs that were signiﬁcantly regulated was found in
liver tissue (7 ERGs) followed by adipose tissue (6 ERGs), uterus tissue
(5 ERGs) and PBMC (3 ERGs). Surprisingly no ERGs were signiﬁcantly
regulated in breast and sternum tissues. Moreover, it appeared that
there was no similarity in the pattern of regulation of the various ERGs
among the diﬀerent tissues.
Because most of the ERGs were not or only slightly regulated by soy
isoﬂavone administration in diﬀerent tissues of ovariectomized rat, we
investigated the genes that were aﬀected most in the three target
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tissues, namely breast, uterus and sternum, by using a ‘fold change (FC)’
threshold. Only signiﬁcantly aﬀected genes with an FC value> 2 were
selected to be investigated for their involvement in diﬀerent biological
processes, and the higher the FC value the more the gene is aﬀected.
Table 2 shows the signiﬁcantly regulated genes, with an FC > 2. In ST,
no genes were regulated with an FC value>2. In breast tissue 14 genes
with an FC > 2 were identiﬁed (i.e. 19% of the signiﬁcantly regulated
genes) of which 13 were up regulated, and in uterus tissue 11 genes (i.e.
1% of the signiﬁcantly regulated genes) of which 9 were up regulated.
According to the information in the NCBI database the up regulated
genes are involved in metabolism such as fatty acid, lipid and glucose
metabolism, in stress responses such as detection of oxidative stress,
responses to abiotic stimuli, defence mechanisms and immune re-
sponses such as cellular response to tumour necrosis factor, antigen
binding, and intercellular signal transduction. Down regulated genes
are involved in DNA and protein binding and inﬂammatory response.
Table 3 shows the signiﬁcantly regulated (p < 0.05) biological
pathways (BPs) in diﬀerent tissues of the present rat study, and the
related human disease, as indicated in the Kyoto Encyclopaedia of
Genes and Genomes (KEGG) data base. The total list of biological
pathways that were signiﬁcantly up- or down regulated in diﬀerent
tissues can be found in supplementary Table 2. A total of 33 diseases
related KEGG based biological pathways were found to be signiﬁcantly
regulated in diﬀerent tissues in the present rat study. The highest
number of up regulated biological pathways was found in uterus tissue
(i.e. 24) and then in breast tissue (i.e. 5), whereas 3 biological pathways
were up regulated in sternum and PBMC. The highest number of down
regulated biological pathways was found in liver tissue (i.e. 19) fol-
lowed by adipose tissue (10), PBMC (7), and uterus tissue (2). Although
only 5 and 3 biological pathways were signiﬁcantly regulated in breast
and sternum tissue, respectively, they all were up regulated, whereas in
liver and adipose all the BPs were down regulated. Interestingly, when
a disease related pathway was signiﬁcantly up regulated in the surro-
gate tissues, PBMC or adipose tissue, it was mostly down regulated in
one or more target tissues, and vice versa. No direct correlation was
found between eﬀects in the surrogate tissues and the target tissues.
Also in the gene set enrichment scatter graphs we made to compare up
and down regulated BPs in diﬀerent surrogate and target tissues (results
not shown), not any correlation was observed.
In Fig. 2 the gene expression patterns in PBMC of the present rat
study were compared to those obtained in the short-term rat study [18].
Only 145 genes were signiﬁcantly regulated in both data sets (data not
shown) of which ﬁfteen marker genes were identiﬁed to be highly
correlated (deviation value 0 to± 10) and their gene expression was
signiﬁcantly changed in the same direction (increased or decreased) in
both studies. As can be concluded from the information included in
supplementary Table 3, most of the genes thus identiﬁed are involved in
biological pathways related to increase in immune response and in cell
proliferation.
In the human intervention studies mentioned above, van der Velpen
et al. [4,19] reported signiﬁcant regulation of ERGs in human PBMC
and adipose tissue following soy isoﬂavone supplementation. Table 4
shows the reported signiﬁcantly expressed ERGs in PBMC of human
volunteers that were also signiﬁcantly regulated in PBMC of the present
Fig. 1. Flow chart of the microarray analysis indicating signiﬁcantly changed genes and gene sets induced in diﬀerent tissues of ovariectomizedF344 rats after oral
gavage dosing (2mg soy isoﬂavones/kg bw per day for 8 weeks) of a commercial soy supplement. The number of corresponding human homologue genes found in
rats is also indicated (right hand column). AT, adipose tissue; BT, breast tissue; LT, liver tissue; PBMC, peripheral blood mononuclear cells; ST, sternum tissue and UT,
uterus tissue.
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rat study. Out of 17 signiﬁcantly changed human PBMC genes, only 1
gene, namely CACYBP, was signiﬁcantly regulated in the rat, although
in opposite direction (up in humans and down in rats), 5 genes were
insigniﬁcantly regulated, and 11 were not diﬀerentially regulated in rat
PBMC at all. In summary, no correlation was found between the eﬀects
on gene regulation in PBMC of the present rat study and those in PBMC
of the study in human volunteers.
Table 5 shows the reported signiﬁcantly expressed ERGs in adipose
tissue of human volunteers [4] and their expression in the adipose
tissue in the present rat study. Out of 82 signiﬁcantly changed ERGs in
human adipose tissue, only 6 genes were also signiﬁcantly changed in
rat adipose tissue, 40 genes were non-signiﬁcantly regulated and 36
genes were not regulated in the rat adipose tissue. Out of the 6 genes
that were signiﬁcantly regulated in both human and rat adipose tissue,
5 were regulated in the same direction (up or down), and 1 (KITLG)
changed in the opposite direction. The down regulated common ERGs
in adipose tissue i.e. NR4A1 and IGF2 have a positive relationship with
diﬀerent BPs such as apoptosis, endothelial cell proliferation, RNA and
DNA transcription, T-cell proliferation etc. (see supplementary Table 4).
Thus down regulation of these genes would lead to inhibition of these
processes. Although some similarities in the response in gene expression
in rat and human adipose tissue following soy isoﬂavone exposure have
been found, there is no clear overall correlation.
Fig. 3 shows a rank-rank scattered plot of the signiﬁcantly regulated
genes in PBMC and adipose tissue in the rat study and in the human
intervention studies. There were 10 human homologous genes sig-
niﬁcantly regulated in rat PBMC, however there was no overall corre-
lation between these 10 genes and the 10 signiﬁcantly regulated human
PBMC genes (Fig. 3a). This implies that the genes which were highest
up regulated in rat PBMC were not the same as those in human PBMC,
and some genes were regulated in the opposite direction. A similar
result was found for the 88 common and signiﬁcantly regulated genes
expressed in rat and human adipose tissue (Fig. 3b). To identify marker
genes, i.e. genes of which the expression was increased or decreased in
the same direction in both rat and human PBMC and adipose tissue
from the rank-rank scattered plots shown in Fig. 3 a and b, deviation
values were used from the corresponding correlation line. For PBMC
(Fig. 3a) a deviation value of 0 to±1 was used, because the number of
overlapping genes was only 10. For adipose tissue (Fig. 3b) a deviation
value of 0 to±4 was used, because the number of overlapping genes
was 88. For PBMC (Fig. 3a) three marker genes were identiﬁed, which
were mainly associated with protein production and regulation of cell
growth (see supplementary Table 5). Similarly 11 marker genes were
Table 1
List of signiﬁcantly (p < 0.05) up and down regulated estrogen-responsive
genes (ERGs) in diﬀerent tissues of ovariectomized rats after 8 weeks oral
dosing with the frequency of one gavage dose/day of a commercial supplement
(2 mg soy isoﬂavones/kg bw) compared with control. Up and down regulated
enrichments were indicated by up and down arrow marks. A list of all ERGs can
found in the Dragon ERG database (https://web.archive.org/web/
20160118215946/http://datam.i2r.a-star.edu.sg/ergdbV2).
Name of the gene PBMC AT BT UT ST LT
AR ↓ ↑ns ↓ns ↓ns ↓ns absent
ANXA4 ↓ns ↓ns ↑ns ↑ns ↓ns ↓
DUSP1 ↓ns ↓ns ↓ns ↓ns ↓ns ↓
IGF1 absent ↑ns ↑ns ↑ns ↑ns ↓
IL6R ↓ns ↑ns ↑ns ↑ ↑ns ↑
IGFBP5 absent ↓ * ↑ns ↓ns ↑ns absent
IGFBP2 absent ↑ * absent absent absent ↓ns
KIT absent ↑ * ↑ns absent absent absent
NR2F6 absent ↓ * absent ↑ns absent ↓ns
PGR absent absent absent ↑ absent absent
PNOC absent ↑ absent ↓ absent absent
PAWR absent ↑ * ↓ns ↓ns absent ↓ns
RARA ↓ * ↓ns ↓ns ↑ns ↓ns ↓
RB1 ↑ns ↑ns ↑ns ↑ns ↓ns ↓
SCARB1 ↓ns ↑ns ↑ns ↑ ↑ns ↑ns
SCP2 ↑ns ↑ * ↑ns ↓ns ↑ns ↑ *
TGFB1 ↓ns ↓ns ↑ns ↑ ↑ns ↓ns
TEP1 ↓ * ↓ns ↓ns ↑ns ↑ns ↓ns
TIMP1 absent ↑ns ↑ns ↑ ↑ns ↓ns
ns = not signiﬁcant.
* genes common in rat and human.
AT, adipose tissue; BT, breast tissue; LT, liver tissue; PBMC, peripheral blood
mononuclear cells; ST, sternum tissue and UT, uterus tissue.
Table 2
List of the signiﬁcantly expressed (fold change> 2 and p < 0.05) genes in diﬀerent target tissues of rats (negative numbers indicate down regulation).
Tissue Gene symbol Description Functions/process Fold change
Breast
tissue
Adipoq Adiponectin, C1Q and collagen domain
containing
Fat cell diﬀerentiation, detection of oxidative stress, fatty acid oxidation and
glucose metabolism.
4.9
Rnase2 Ribonuclease, RNase A family, 2 (liver,
eosinophil-derived neurotoxin)
A protein-coding gene involved in nucleic acid binding. 4.5
Mcpt1l1 Mast cell protease 1-like 1 Involved in proteolysis (protein breakdown). 2.9
Cpa3 Carboxypeptidase A3, mast cell A protein-coding gene involved in zinc ion binding 2.9
Thrsp Thyroid hormone responsive Lipid metabolism biosynthesis process. 2.8
Cd163 CD163 molecule Receptor mediated endocytosis 2.3
Tusc5 Tumour suppressor candidate 5 Involved in the response to the biotic stimulus 2.3
Cdo1 Cysteine dioxygenase type 1 Metabolism of cysteine 2.3
Fabp4 Fatty acid binding protein 4, adipocyte Fat cell diﬀerentiation, cholesterol homeostasis, fatty acid metabolism and
cytokine production
2.2
Prkar2b Protein kinase, cAMP dependent regulatory, type
II bet
Fatty acid metabolism 2.1
Mpz Myelin protein zero Cell-cell junction maintenance 2.1
Atf3 Activating transcription factor 3 Involved in DNA and protein binding, −2.1
Uterus
tissue
LOC684146 Ig kappa chain V-II region 26-10-like No information provided by NCBI database 10.2
Igkv28 Immunoglobulin kappa chain variable 28 No information provided by NCBI database 8.7
LOC500181 Ig kappa chain V-V region K2-like No information provided by NCBI database 3.4
Igj Immunoglobulin joining chain A protein-coding gene involved in antigen binding 2.9
Nos2 Nitric Oxide Synthase 2, Inducible Involved in aging, cellular response to tumour necrosis factor, intracellular
signal transduction and nitric acid biosynthetic process
2.8
Mzb1 Marginal zone B and B1 cell-speciﬁc protein Involved in integrin activation, regulation of B cell proliferation and positive
regulation of immunoglobulin biosynthetic process
2.7
LOC100361706 Lambda-chain C1-region-like Involved in antigen binding 2.5
LOC362795 Immunoglobulin G heavy chain Involved in antigen binding 2.2
Fgg Fibrinogen gamma chain Involved in inﬂammatory response, platelet activation and aggregation −2.1
Rup2 Urinary protein 2 No information provided by NCBI database −3.9
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identiﬁed for adipose tissue (Fig. 3b). As can be seen in the supple-
mentary table 6, these marker genes appeared to be involved in bio-
logical processes related to immune and inﬂammatory responses. In
addition scattered plots were made using all homologous genes (i.e.
6413 homologous genes for human and rat PBMC and 7731 homo-
logous genes for human and rat adipose tissue, see Fig. 1) without
applying any signiﬁcant cut-oﬀ value, but also in this situation no
correlation between results in rats and humans was observed (results
not shown).
4. Discussion
The results of this eight week study in ovariectomized rats show that
the overall gene expression data after soy isoﬂavone supplementation
are tissue speciﬁc for the regulation of estrogen responsive genes
(ERGs) (see Table 1), and even more for genes not known to be ERGs.
The diﬀerent responses in gene expression in diﬀerent tissues might be
explained diﬀerent ERα/ERβ ratios in these tissues [11–14]. This may
complicate the use of surrogate tissues like PBMC or adipose tissue to
predict the eﬀects in target tissues such as breast, uterus or sternum
tissue. In addition to diﬀerences in gene regulation upon soy isoﬂavone
supplementation among diﬀerent tissues, there also appeared to be a
considerable diﬀerence in gene expression in the same tissue of the
same species upon diﬀerent exposure duration, as was evident by the
absence of a correlation between the gene expression data in PBMC
collected in the short- and the long-term rat study (see Fig. 2). We also
did not observe a correlation between changes in gene expression in
similar tissues (PBMC and adipose tissue) from rats and humans upon
similar dosing and exposure duration (see Fig. 3; Table 4 and 5).
It was the aim of the present study to investigate whether it was
possible to predict the eﬀect of soy isoﬂavones supplementation in
human target tissues, such as breast, uterus or sternum tissue. This was
Table 3
Signiﬁcantly (p value<0.05) regulated biological pathways after 8 weeks oral
administration of a commercial soy supplement in ovariectomized rats. Only
KEGG based biological pathways were included that were related to a distinct
human disease. Up and down regulation is indicated by up and down arrows.
KEGG BASES BPs PBMC AT LT BT ST UT
Alzheimer's disease ↑ ↓ ns ns ns ns
Parkinson's disease ↑ ↓ ns ns ns ↓
Huntington's disease ↑ ↓ ns ns ns ns
Prion diseases ns ↓ ↓ ns ns ns
Bacterial invasion of epithelial cells ns ↓ ↓ ↑ ns ↑
Leishmaniasis ↓ ↓ ↓ ns ns ↑
Chagas disease (americantrypanosomiasis) ns ns ns ns ↑ ↑
African trypanosomiasis absent absent ns ns ns ↑
Malaria ns ns ↓ ↑ ↑ ↑
Toxoplasmosis ns ns ↓ ns ns ↑
Amoebiasis ns ns ↓ ns ↑ ↑
Staphylococcus aureus infection ↓ ns ↓ ↑ ns ↑
Hepatitis c ns ns ns ns ns ↑
Pathways in cancer ns ns ↓ ns ns ↑
Pancreatic cancer ns ns ↓ ns ns ↑
Glioma ns ns ↓ ns ns ↑
Thyroid cancer ns ns ns ns ns ↑
Melanoma ns ns ↓ ns ns ns
Bladder cancer ns ns ↓ ns ns ns
Chronic myeloid leukemia ns ns ns ns ns ↑
Acute myeloid leukemia ↓ ns ns ns ns ↑
Small cell lung cancer ns ns ↓ ns ns ↑
Non-small cell lung cancer ns ns ns ns ns ↑
Autoimmune thyroid disease ↓ ns ns ns ns ↑
Systemic lupus erythematosus ns ns ↓ ↑ ns ↑
Rheumatoid arthritis ns ↓ ↓ ↑ ns ↑
Allograft rejection ↓ absent ns ns ns ↑
Graft-versus-host disease ↓ absent ns ns ns ↑
Primary immunodeﬁciency ↓ absent ns ns ns ↑
Hypertrophic cardiomyopathy (hcm) ns ↓ ↓ ns ns ↓
Arrhythmogenic right ventricular
cardiomyopathy (ARVC)
ns ↓ ↓ ns ns ns
Dilated cardiomyopathy ns ↓ ↓ ns ns ns
Viral myocarditis ns ↓ ↓ ns ns ↑
ns = not signiﬁcant.
BPs, biological pathways; AT, adipose tissue; BT, breast tissue; LT, liver tissue;
PBMC, peripheral blood mononuclear cells; ST, sternum tissue and UT, uterus
tissue.
Fig. 2. Rank-rank scattered plot for signiﬁcantly changed common PBMC genes
in the current long-term rat study (i.e. 8 week exposure) and from the group
exposed to the same dose (i.e. 2 mg soy isoﬂavones/kg bw per day) in the short-
term (2 days) rat study [18]. Each dot represents the t-value of a single gene
and the highlighted dots (♦) indicate the highly correlated genes. The list of
these 15 genes can be found in supplementary Fig. 3. Genes signiﬁcantly
changed in the same direction in both treatments are in Cartesian quadrants I
and III, while genes signiﬁcantly changed in opposite directions are in quad-
rants II and IV.
Table 4
List of the signiﬁcantly expressed human estrogen responsive genes (ERGs) in
PBMC of human volunteers reported by van der Velpen et al. [19] and their
expression in rat PBMC in the present long-term rat study. Up and down
regulated gene expressions are indicated by up and down arrows.
Genes Description Regulation
Human Rat
BCL2L1 BCL2-like 1 ↑ a
CACYBP Calcyclin binding protein Y ↓ ↑
EDEM1 Endoplasmatic reticulum degradation enhancer,
mannosidase alpha-like 1
↑ ↑ns
ERBB2 V-ERB-B2 erythroblasticleukemia viral oncogene
homolog 2 neuro/glioblastoma derived oncogene
homolog (avian)
↑ a
FKBP5 FK506 binding protein 5 ↑ a
FOXP1 Forkhead box P1 ↑ ↓ns
HSPA1 A Heat shock 70 kDa protein 1 A Y ↓ a
aMYB v-mybmyeloblastosis viral oncogene homolog (avian) ↑
NME2 NME/NM23 nucleoside diphosphate kinase 2 Y ↓ ↑ns
NRP1 Neuropilin 1 Y ↓ ↓ns
PSMD8 Proteasome (prosome, macropain) 26S subunit, non-
ATPase, 8 Y
↓ ↑ns
PTPRO Protein tyrosine phosphatase, receptor type, O Y ↓ a
SLC25A5 Solute carrier family 25 (mitochondrial carrier;
adenine nucleotide translocator), member 5
↓ a
SPRED1 Sprouty-related, EVH1 domain containing 1 Y ↓ a
STAB1 Stabilin 1 Y ↓ a
STXBP1 Syntaxin binding protein 1 ↑ a
TIMELESS Timeless homolog (Drosophila) ↓ a
a = absent.
ns = not signiﬁcant.
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Table 5
Signiﬁcantly expressed human estrogen responsive genes (ERGs) in adipose tissue of human volunteers reported by van der Velpen et al. [4] and their expression in
adipose tissue in the present long-term rat study. Up and down regulated gene expressions are indicated by up and down arrows.
Sl. No. Genes Description Regulation
Human Rat
1 NR4A1 nuclear receptor subfamily 4, group A, member 1 ↓ ↓
2 RET ret proto-oncogene ↓ a
3 TK1 thymidine kinase 1, soluble ↓ a
4 TGFB3 transforming growth factor, beta 3 ↓ ↑ns
5 NOS3 nitric oxide synthase 3, endothelial cell ↓ ↓ns
6 GOT1 glutamic-oxaloacetic transaminase 1, soluble ↓ ↓ns
7 TNC tenascin C ↓ a
8 IGF2 insulin-like growth factor 2 ↓ ↓
9 PPIF peptidylprolylisomerase F ↓ ↑ns
10 ME1 malic enzyme 1, NADP(+)-dependent, cytosolic ↓ ↓ns
11 NME1 NME/NM23 nucleoside diphosphate kinase 1 ↓ a
12 TUBG1 tubulin, gamma 1 ↓ ↑ns
13 THBD Thrombomodulin ↓ a
14 NCAM2 neural cell adhesion molecule 2 ↓ a
15 KITLG KIT ligand ↓ ↑
16 ELOVL2 ELOVL fatty acid elongase 2 ↓ a
17 CCND1 cyclin D1 ↓ ↑ns
18 CNKSR3 CNKSR family member 3 ↓ a
19 CYCS cytochrome c, somatic ↓ a
20 DHCR24 24-dehydrocholesterol reductase ↓ ↓ns
21 KIR3DL2 killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 ↓ a
22 PAICS phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazolesuccinocarboxami ↓ a
23 TFF1 trefoil factor 1 ↓ a
24 HSPD1 heat shock protein 1 (chaperonin) ↓ ↑ns
25 KPNA2 karyopherin alpha 2 (RAG cohort 1, importin alpha 1) ↓ a
26 ARMCX3 armadillo repeat containing, X-linked 3 ↓ ↑ns
27 ENO1 enolase 1, (alpha) ↓ ↑ns
28 SGCD sarcoglycan, delta (dystrophin-associated glycoprotein) ↓ ↓ns
29 SEMA5B sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembranedomai ↓ a
30 G6PD glucose-6-phosphate dehydrogenase ↓ ↑ns
31 RAMP3 receptor (G protein-coupled) activity modifying protein 3 ↓ a
32 AURKB aurora kinase B ↓ a
33 ESR2 estrogen receptor 2 (ER beta) ↓ a
34 C1QBP complement component 1, q subcomponent binding protein ↓ ↑ns
35 CENPA centromere protein A ↓ a
36 ACO2 aconitase 2, mitochondrial ↓ ↑ns
37 RUNX1 runt-related transcription factor 1 ↓ ↓
38 MCM4 minichromosome maintenance complex component 4 ↓ a
39 NR4A3 nuclear receptor subfamily 4, group A, number 3 ↓ a
40 FOXF1 forkbead box F1 ↓ a
41 ORMDL2 ORM1-like 2 (S. cerevisiae) ↓ ↑ns
42 MARCKS myristoylated alanine rich protein kinase C substrate ↓ ↑ns
43 SLC12A2 solute carrier family 12 (sodium/potassium/chloride transporter), member 2 ↓ ↑ns
44 SPRY1 sprout homolog 1, antagonist of FGF signaling (Drosophila) ↓ a
45 GARS glycyl-tRNAsynthetase ↓ ↓ns
46 RPA3 replication protein A3 ↓ ↑ns
47 STMN1 stathmin 1 ↓ a
48 IARS isoleucyl-tRNAsynthetase ↓ ↓ns
49 ITGAV integrin, alpha V ↓ ↑ns
50 NUP88 nucleoporin 88 ↓ ↑ns
51 TXNIP thioredoxin interacting protein ↑ ↑ns
52 NRF1 nuclear respiratory factor 1 ↑ ↑ns
53 ECE1 endothelin converting enzyme 1 ↑ ↑ns
54 EFEMP1 EGF-containing ﬁbulin-like extracellular matrix protein 1 ↑ ↑
55 MPL Myelo-proliferative leukemia virus oncogene ↑ a
56 GSTO1 glutathione S-transferase omega 1 ↑ ↑ns
57 HIP1R huntingtin interacting protein 1 related ↑ a
58 PAX8 paired box 8 ↑ a
59 PTPN18 protein tyrosine phosphatase, non-receptor type 18 (brain-derived) ↑ a
60 WSB1 WD repeat and SOCS box-containing 1 ↑ ↑ns
61 IGF1R insulin-like growth factor 1 receptor ↑ ↑ns
62 GNG7 guanine nucleotide binding protein (G protein), gamma 7 ↑ a
63 SFRP1 secreted frizzled-related protein 1 ↑ ↑ns
64 MCM7 minichromosome maintenance complex component 7 ↑ ↑ns
65 SATB1 SATB homeobox 1 ↑ ↓ns
66 INPP4B inositol polyphosphate-4-phosphatase, type II ↑ ↓ns
67 THBS2 thrombospondin 2 ↑ ↑ns
68 PTGER2 prostaglandin E receptor 2 (subtype EP2), 53kDa ↑ a
69 WISP2 WNT1 inducible signaling pathway protein 2 ↑ ↑
70 BCL2L11 BCL2-like 11 (apoptosis facilitator) ↑ a
71 ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 ↑ a
(continued on next page)
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done by evaluating the similarities in the gene expression pattern of the
surrogate tissues PBMC and adipose tissue in rats and humans after
administration of the similar oral dose of a commercially available soy
isoﬂavone containing supplement. Because the results of the surrogate
tissues (PBMC and adipose tissue) in rats diﬀered from those in humans,
and because there was no correlation between changes in gene ex-
pression between surrogate and target tissues in rats, we were un-
fortunately not able to predict possible health eﬀects in humans.
Although transcriptomic techniques are a powerful tool to predict early
biological eﬀects, it appeared to be complicated to interpret early
changes in gene expression proﬁles in relation to adverse or beneﬁcial
responses related to diﬀerent biological processes.
In our earlier short term rat experiment [18] we have found that
after exposure of ovariectomized rats for 2 days to the same supplement
as used in the present study, 3861 genes were signiﬁcantly regulated in
PBMC. In the present 8 weeks study the number of regulated genes in
PBMC was signiﬁcantly smaller (470 genes). Compared with the total
number of probes in the microarray, the number of signiﬁcantly regu-
lated genes in the short term study was 20% and in the long term study
only 2.4%. Interestingly, in the human intervention study reported by
van der Velpen et al. [19] it was found that 357 genes were signiﬁcantly
regulated in human PBMC, which was about 1.8% of the total probe
sets. Possibly long-term exposure might induce homeostasis, resulting
in a smaller number of regulated genes in PBMC gene expression pro-
ﬁles, in both rats and humans.
The commercial supplement used in the present rat study contains
predominantly daidzin glucoside (about 57%). After enzymatic hydro-
lysis, converting the total amount of conjugated and non-conjugated
soy isoﬂavones into non-conjugated aglycones, only daidzein and its
metabolite equol were detected in the rat plasma samples. The average
plasma concentrations of daidzein and equol were 0.25 and 0.38 μM,
respectively (see supplementary table 7). Hosada et al. [34] and Gu
et al. [35] reported that at best 3% of the total amount of soy iso-
ﬂavones in the systemic circulation could be present as free bioactive
aglycones. Based on this information it can be estimated that a total
plasma concentration of free aglycones in rat plasma of about 19 nM
(7.5 nM free diadzein aglycone and 11.4 nM free equol aglycone) could
have been reached. Fig. 4 shows the estrogenic dose response curves of
daidzein in vitro model systems detecting the induction of luciferase
activity in diﬀerent human osteosarcoma cells i.e. U2OS-ERα and
U2OS-ERβ cells and proliferation in diﬀerent breast cancer cells i.e.
T47D-wt and T47D-ERβ cells as has been previously reported by us
[36]. For the estimated total free aglycone concentration in the current
rat study (plotted as vertical line in Fig. 4). It can be seen that this
concentration is unlikely to induce an ERα related response, but that it
could be able to induce a moderate ERβ related response. This ob-
servation might be an explanation for the low responses in gene ex-
pression, including for ERGs, as observed in the present rat study.
It should be noted, however, that this comparison of the total free
aglyone concentration of 19 nM with the in vitro estrogenic response of
daidzein does not consider diﬀerences in estrogenic potency between
daidzein and equol. It is known that equol might have a higher estro-
genic potency than daidzein, and therefore the use of the concentration
of 19 nM for an expected estrogenic eﬀect might be an underestimation.
Unfortunately, no formal relative potency factor for the comparison of
daidzein and equol is available. However, several authors have ad-
dressed the diﬀerence in estrogenic potency between daidzein and
equol in various test systems. Hwang et al. 2006 [3] using four diﬀerent
cell lines (i.e. human breast cancer cell line MCF-7, human embryonic
kidney cells 293, murine calvarias osteoblasts MC3T3E1, and murine
Table 5 (continued)
Sl. No. Genes Description Regulation
Human Rat
72 TSC22D3 TSC22 domain family, member 3 ↑ a
73 NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha ↑ ↑ns
74 ANKRD44 ankyrin repeat domain 44 ↑ ↑ns
75 CTNND1 catenin (cadherin associated protein), delta 1 ↑ ↑ns
76 BCL2L1 BCL2-like 1 ↑ a
77 TNFSF8 tumour necrosis factor (ligand) superfamily, member 8 ↑ a
78 CCNG2 cyclin G2 ↑ ↑ns
79 FKBP8 FK506 binding protein 8 ↑ ↓ns
80 ZFP36L2 zinc ﬁnger protein 36, C3H type-like2 ↑ a
81 SLA Src-like adaptor ↑ ↑ns
82 S100P S100 calcium binding protein P ↑ a
a = absent.
ns = not sigsssssssniﬁcant.
Fig. 3. Rank-rank scattered plot for sig-
niﬁcantly changed common PBMC genes in rat
and (post)menopausal women (3a), and sig-
niﬁcantly changed common genes in adipose
tissue of rats and (post)menopausal women
(3b). Each dot represents the t-value of a single
gene and the highlighted dots (♦) indicate the
correlated genes. Corresponding human
homologous genes were retrieved from the
study with (post)menopausal women taking
the same supplement, in a similar dose (about
1.5 mg soy isoﬂaone/kg bw per day) and time
duration (i.e. 8 weeks) [4,19]. Genes sig-
niﬁcantly changed in the same direction in
both treatments are in Cartesian quadrants I
and III, while genes signiﬁcantly changed in
opposite directions are in quadrants II and IV.
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monocytic cells RAW 264.7) transfected with the estrogen-responsive
reporter gene construct 3×ERE-TATA-Luc found that the transcrip-
tional potency of equol for the ERα receptor was 1.1 fold higher and for
ERβ receptor 1.2 fold higher than that of daidzein.
Kalita and Milligan [37] using Ishikawa and yeast cells, expressed
the relative potencies of diﬀerent estrogenic compounds compared to
estradiol (E2) and reported that the relative potency of equol is about
2–8 fold higher than that of daidzein. Comparable values, ranging from
1–4.7, have been reported in two review papers [38,39]. In contrast to
these results a much higher potency factor of 100 was reported by
Sathymoorthy and Wang [40] based on proliferation and mRNA ex-
pression of the oestrogen-responsive pS2 gene in MCF7 cells. Because
the reported relative potencies of equol compared to daidzein, based on
diﬀerent test systems, diﬀer considerably, no distinct overall potency
factor can be established. But based on the available data we assumed a
reasonable estimate of a factor of 10 for the relative potency of equol
compared to daidzein. Thus the concentration of 19 nM as mentioned
above could be converted into about 120 nM daidzein aglycone
equivalents. As can be seen by the dotted lines in Fig. 4 the conclusion
drawn above that the plasma levels as observed in the current rat study
would not be able to induce an ERα related response, but could induce
a moderate ERβ related response, is still valid.
For comparison with the rat study we also calculated the total free
aglycone concentrations in plasma of human volunteers in the human
intervention study where in addition to daidzein and equol, also gen-
istein and glycitein were detected [19]. After converting the μg/mL
concentrations reported by these authors to nM and using again a value
of 3% for the amount of soy isoﬂavones that can be present in the
circulation in the free form (see above), the total free aglycone con-
centration in these human volunteers could be estimated to be about
130 nM, on average. This is about 6.8 fold higher than the free agly-
cones concentration in rat plasma. Considering that the daidzein con-
centration in human plasma is highest (0.47 μg/mL) followed by equol
(0.35 μg/mL), and that lower concentrations were found for genistein
(0.18 μg) and glycitein (0.12 μg/mL), one could speculate that, even
considering the higher potency of equol compared to daidzein, the
concentrations of free aglycones in human plasma were also not able to
induce a signiﬁcant ERα related response, but that a signiﬁcant ERβ
related response could be possible (Fig. 4). This might explain the
beneﬁcial health eﬀects that have been reported in several human in-
tervention studies or randomised control trails, such as alleviation of
menopausal eﬀects [4,5,40–42]. But activation of ERβ is also associated
with anti-proliferative and anti-carcinogenic eﬀects in hormone sensi-
tive breast cancer patients [33,43].
The observed diﬀerence in plasma concentration between rats and
humans after administration of the same soy isoﬂavone supplement at a
similar dose level (2 mg soy isoﬂavone/kg bw) and for the same dura-
tion (i.e. 8 weeks) can be due to species variation in ADME character-
istics and/or a diﬀerence in the dosing regimen. In the present study the
rats were dosed once per day in the morning and in the human inter-
vention study the volunteers took 2 capsules in the morning and 2 in
the evening after the meal. Gu et al. [35] also observed considerable
species diﬀerences in plasma soy isoﬂavone concentrations between
female adult Sprague-Dawley rats and premenopausal woman volun-
teers 4 h after a similar single dose; the concentration of total daidzein
was 4 fold higher in human plasma compared to that of the rat. This is
in line with the results of the present study. Setchell et al. [40] also
found signiﬁcant species diﬀerences in the circulating concentrations of
aglycones between rodents and humans. Based on diﬀerences in the
proportion of unconjugated soy isoﬂavone in plasma of humans and
that of rodents, particularly in certain strains of mice, they also ques-
tioned the value of rodent models for the assessment of eﬀects of soy
isoﬂavone in humans. However, Setchell et al. [40] used diﬀerent iso-
ﬂavone sources and administration protocols to treat animals and
human volunteers, and animals were treated with much higher dose
levels compared to humans, leading to higher aglycone concentrations
in the plasma of rats compared to humans. In addition, the adult hu-
mans span a wide range of ages (i.e. from 21 to 65 years).
Fig. 4. Comparison of the estimated in vivo
concentration of total free aglycones with the
concentration-response curve of daidzein in
diﬀerent in vitro cell models for estrogenicity.
(Figure adapted from Islam et al. [36]). The
solid lines indicate the expected eﬀect of the
total free aglycones present in the rat plasma,
the dotted lines taking into account the higher
estrogenic potency of equol compared to
daidzein.
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We also investigated a number of pathways in the rat that might
have been aﬀected by soy isoﬂavone treatment. In the present study the
PPAR signalling pathway was up regulated in breast uterus and liver
tissues (see supplementary Table 2) indicating a positive eﬀect of soy
isoﬂavone treatment. However, this pathway was signiﬁcantly down
regulated in human PBMC following administration of the same sup-
plement. Other studies have shown that both ERs and PPARs can in-
ﬂuence each other and thus might lead to diﬀerent eﬀects of soy iso-
ﬂavone [45,46]. It has been reported that soy isoﬂavone are capable to
bind and activate all three isoforms namely, PPARα, PPARβ and PPARγ,
of the peroxisome proliferator-activated receptors (PPARs) [44]. These
PPARs are a group of transcription factors, which play an essential role
in the regulation of cellular diﬀerentiation, carbohydrate, lipid and
protein metabolism and tumorigenicity [44]. It was found that the p53
pathway was signiﬁcantly up regulated in PBMC and breast tissue of
rats (see supplementary Table 2). P-53 is an important and one of the
most studied stress response pathways conserving stability of DNA, and
protecting cells from DNA damage [47]. Under normal conditions this
tumour suppressor gene is constitutively expressed, but it is negatively
regulated by the pathway sensor called Mdm2, and then degraded.
However, a variety of stress events in the cells, especially those related
to DNA damage, activate a series of events that stabilize thep53 protein
by inhibiting its degradation. Once activated p53 regulates divergent
groups of target genes related to cell cycle arrest [48], DNA repair
mechanism [49,50] and induction of apoptosis [51]. Hence activation
of this p53 gene has been reported to be associated with prevention of
cancer. Therefore up regulation of the p53 pathway, as observed in the
present rat study, could be considered as a possible beneﬁcial eﬀect of
exposure to soy isoﬂavones.
Given the fact that the correlations in gene expression in PBMC and
adipose tissue between the present rat study and the human interven-
tion study, both using the same soy isoﬂavones supplement, were lim-
ited, it is of importance to consider the possible limitations of the
current rat study. In the rat study the animals were dosed once per day
by gavage, whereas the human volunteers took the dose in two portions
per day. This diﬀerence in dose regimen, together with possible eﬀects
of the circadian cycle could have inﬂuenced the gene expression.
Furthermore, the comparison of the eﬀects of soy isoﬂavones in rats and
humans was based on the use of a similar external dose, and no con-
sideration was given to the internal dose. As indicated above, higher
plasma concentrations of soy isoﬂavones were found in humans com-
pared to the rat. We previously reported that rats can metabolize soy
isoﬂavone faster than humans [21]. So providing the same external
dose on a kg/bw basis appeared to result in somewhat dissimilar plasma
concentration in rats and humans, and this could have contributed to
the diﬀerences in gene expression between rats and humans, as ob-
served in the present study.
In our study we have used young ovariectomized rats and con-
sidered them as a suitable model for (post)menopausal women.
Although it is a well-established model, it also have its limitations.
Brinton [52] mentioned that ovariectomy is a widespread model of
menopause and is typically done by removing ovaries from young re-
productively competent healthy animals. The limitations he mentioned
about the ovariectomy model of menopause are that in this model it is
assumed that ovaries are the only organs capable of producing ovarian
hormones and therefore, plasma levels of ovarian hormones are in-
dicative of ovarian hormone concentrations in organs. However, this
assumption was challenged by Caruso et al. [53], who found that
changes in plasma levels of neuroactive steroid levels after gona-
dectomy do not necessarily reﬂect the steroid levels in either the per-
ipheral or central nervous system. Secondly, in our experiments out-
comes obtained from analyses of short-term ovariectomy are
generalized to long-term ovarian hormone deprivation. However, this
assumption ignores the adaptive responses that organs can undergo to
compensate for the loss of ovarian hormones. Although removal of the
ovaries in young animals is a model that broadly generalizes to human
menopause. This assumption can also be challenged because adapta-
tions can occur in the estrogen-regulated metabolic pathways during
aging. In humans, ovarian hormone deprivation is chronic, in case no
hormone therapy is initiated. According to the review of Brinton [52]
chronic exposure in animal models is entirely feasible of human me-
nopause. It can be thus concluded that fully developed, aged female rats
may have better physiological similarities with (post)menopausal
women and may therefore be a more appropriate animal model.
5. Conclusion
In the present study there are considerable diﬀerences in gene ex-
pression between various surrogate and target tissues. In addition, no
cross-species early biomarkers for health eﬀects of soy isoﬂavone could
be identiﬁed. Based on these results it can be concluded that the use of
transcriptomic data in young ovariectomized rats is challenging, but
does not provide a suitable model for human risk or beneﬁt analysis for
soy isoﬂavone supplementation.
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